When to Choose Aura-O™?
High risk women— with Polycystic Ovarian Syndrome (PCOS)
Avoid unnecessary treatment and protect fertility️
Distinguish non-cancerous conditions (Endometriosis & Fibroids) from early signs of malignancy
Monitor your health
after during treatment
Irregular Periods or Unusual Bleeding after Menopause
Family History
of Cancers
Aura-O™ Ovarian Cancer Screening Process (Minimally Invasive)
Step 01
Schedule Screening and Get IDBook your appointment and receive an activation ID for secure tracking and results access.
Step 03
Blood Sample CollectionA small 5ml blood sample will be gently collected for a quick and easy experience.
Why Aura-O™ is a Game-Changer for Women’s Health?
Non-Invasive Sample Collection
Uses ctDNA from a small venous
blood draw with no surgery, no
biopsy and no discomfort.
Early Detection of FIGO Stages
84.6%
88.9%
84.8%
91.7%
Detection Sensitivity (%)
DNA Methylation-Based Assay
Targets clinically validated
markers (CDO1 and HOXA9)
for high sensitivity and,
specificity.
High Accuracy
89.7%
97.5%
Efficient Triage Tool
CE-IVD Certified
Approved for clinical use. More accurate and cost-effective than CA125, HE4,
and ROMA Index.
Aura-O™ Outperforms
Traditional Ovarian Cancer Detection Methods
Sensitivity
Specificity
Percentage (%)
Clinical Trials Insights
Validated in 6,600+ patients, showing >90% accuracy and superior early-stage
ovarian cancer detection vs. CA125, HE4, and ROMA; CE-IVD marked.
What You Receive
Gynecology Consultation
Get a personalised consultation with a
gynecologist to discuss your results
and next steps.
Further Screening or Treatment
If needed, you’ll receive recommendations
for additional screening or
treatment.
